Menaquinones (Vitamin K2 ) : Physiology, Evidence, and Clinical Translation

Vitamin K2: The Menaquinone Chaperone at the Intersection of Coagulation, Vascular Calcification, and Mitochondrial Energetics

Vitamin K2 is not a single molecule but a family of bacterial and tissue-derived menaquinones, characterized by a 2-methyl-1,4-naphthoquinone ring structure attached to a polyisoprenoid side chain of variable length. This side chain, designated by the number of isoprene units (MK-4 through MK-14), distinguishes the menaquinones from phylloquinone (vitamin K1), the plant-derived form that bears a phytyl side chain, and it is the structural feature that determines the tissue distribution, the half-life, and the spectrum of biological activity of K2. The naphthoquinone ring is the redox-active core that enables vitamin K to function as an essential cofactor for the gamma-glutamyl carboxylase, an endoplasmic reticulum enzyme that converts specific glutamic acid residues to gamma-carboxyglutamic acid (Gla) in a select group of proteins. This post-translational modification confers calcium-binding capacity to these proteins, transforming them from inert polypeptides into functional participants in hemostasis, bone mineralization, the inhibition of soft tissue calcification, and the regulation of cellular growth and survival. Vitamin K1 is preferentially trafficked to the liver, where it supports the synthesis of the hepatic coagulation factors. Vitamin K2, particularly the long-chain menaquinones MK-7, MK-8, and MK-9, is distributed to extrahepatic tissues, where it activates the extrahepatic Gla-proteins that govern the structural integrity of the skeleton and the vasculature. At pharmacological doses, MK-4 also functions as a ligand for the steroid and xenobiotic receptor (SXR), a nuclear receptor that regulates the expression of genes involved in bone formation and osteoclastogenesis, a mechanism entirely distinct from its cofactor role. This monograph is written for the reader who seeks to understand why vitamin K2, long overshadowed by K1 in the clinic as a simple antidote to warfarin, is now recognized as an independent determinant of vascular health, bone strength, and insulin sensitivity, and why the dissociation between hepatic and extrahepatic vitamin K status is a clinically relevant phenomenon with therapeutic implications. We dissect the molecular logic that makes the menaquinones a distinct biological entity from phylloquinone, grade the evidence for their therapeutic application, and map the clinical terrains where vitamin K2 status is a modifiable variable that sits at the nexus of calcification biology and healthy aging.

---

Part 1. The Structural and Metabolic Identity of Vitamin K2

The vitamin K family is defined by the 2-methyl-1,4-naphthoquinone ring, a lipid-soluble aromatic structure that undergoes a cyclic reduction and re-oxidation during the carboxylation reaction. The nomenclature distinguishes the forms by the structure of the side chain attached at the 3-position of the ring. Phylloquinone (K1) has a monounsaturated phytyl side chain. The menaquinones (K2) have a polyunsaturated polyisoprenoid side chain, and they are designated as MK-n, where n denotes the number of isoprenyl units. The most biologically significant menaquinones in humans are MK-4, which is unique in being produced endogenously by tissue-specific conversion from phylloquinone or menadione, and the long-chain menaquinones MK-7, MK-8, and MK-9, which are of bacterial origin, either from the distal gut microbiota or from fermented foods. The length and saturation of the side chain dictate the lipophilicity, the binding affinity for lipoprotein carriers, the circulating half-life, and the tissue distribution. MK-4 has a short half-life of approximately 1 to 2 hours and is concentrated in tissues such as the brain, the pancreas, the testis, and the salivary glands, where it is synthesized locally by the enzyme UBIAD1. MK-7 has a much longer half-life of approximately 2 to 3 days due to its stronger binding to low-density lipoproteins, and it is the primary circulating menaquinone that sustains extrahepatic vitamin K status over time.

1A. Dietary Sources and the Gut Microbiome Contribution

Phylloquinone is obtained from green leafy vegetables, where it is a component of the chloroplast photosynthetic apparatus. Menaquinones are obtained from animal products, particularly organ meats, egg yolks, and full-fat dairy products from grass-fed animals, where MK-4 is the dominant form, and from fermented foods. Natto, a traditional Japanese food made from soybeans fermented with Bacillus subtilis natto, is the richest known dietary source of MK-7, containing concentrations that are orders of magnitude higher than those in any other food. The human gut microbiome, specifically the Bacteroides and Enterococcus species in the distal colon, synthesizes long-chain menaquinones, principally MK-8 through MK-11. The contribution of this endogenous colonic production to systemic vitamin K status has been debated because the menaquinones are embedded in bacterial membranes and may not be bioavailable for absorption in the colon, where bile acids are absent and the absorptive surface for lipids is limited. The current consensus is that the colonic synthesis of menaquinones makes a minor and non-essential contribution to human vitamin K status, and that the dietary intake of K2, or its tissue-specific synthesis from K1, is necessary for optimal extrahepatic Gla-protein activation.

1B. Absorption, Lipoprotein Transport, and Tissue Delivery

Phylloquinone and the dietary menaquinones are absorbed from the jejunum in a process that requires the formation of mixed micelles with bile salts and the subsequent incorporation into chylomicrons by the enterocyte. The efficiency of absorption of phylloquinone from vegetables is relatively low, approximately 10 to 20 percent, and is markedly enhanced by the co-ingestion of dietary fat. MK-7 from natto is absorbed more efficiently, likely due to its presentation in a partially lipid-hydrolyzed matrix. The vitamin K species are carried in chylomicrons to the liver, where they are taken up by the hepatocyte. The liver is the primary site of phylloquinone accumulation, and hepatic vitamin K is the pool that drives the synthesis of the coagulation factors. The liver re-secretes vitamin K into the circulation in very-low-density lipoproteins (VLDL), which are then metabolized to low-density lipoproteins (LDL). The long-chain menaquinones, particularly MK-7, are preferentially incorporated into LDL and have a much longer residence time in the circulation than phylloquinone, which is rapidly cleared by the liver. This extended half-life of MK-7 allows it to be available for uptake by extrahepatic tissues, including bone, the arterial wall, and the pancreatic beta cell, over a period of days rather than hours. This pharmacokinetic difference is the pharmacological basis for the use of MK-7, rather than K1, as a supplement for extrahepatic indications.

1C. The Vitamin K Cycle and the Gamma-Carboxylation Reaction

The active cofactor for the gamma-glutamyl carboxylase is the reduced, hydroquinone form of vitamin K. In the carboxylation reaction, the reduced vitamin K is oxidized to vitamin K 2,3-epoxide, and the energy of this oxidation is harnessed to abstract a proton from the gamma-carbon of a specific glutamic acid residue in the target protein, enabling the addition of a carbon dioxide molecule to form gamma-carboxyglutamic acid. This modification adds a second, negatively charged carboxyl group to the amino acid side chain, creating a calcium-chelating site. The Gla-proteins bind calcium ions through these modified residues, and this calcium binding is essential for their structural conformation and their biological function.

To sustain the carboxylation reaction, the oxidized vitamin K epoxide must be reduced back to the active hydroquinone form. This reduction occurs in a two-step process catalyzed by the enzyme vitamin K epoxide reductase (VKORC1), which is the molecular target of warfarin and related coumarin anticoagulants. Warfarin inhibits VKORC1, trapping vitamin K in the epoxide form and depleting the pool of the reduced cofactor, thereby preventing the gamma-carboxylation of the vitamin K-dependent proteins. The clinical consequence is a functional vitamin K deficiency that impairs the synthesis of the coagulation factors and, over time, the extrahepatic Gla-proteins as well. This is the mechanism by which long-term warfarin therapy can contribute to vascular calcification, a finding that has been observed clinically and that provides a powerful piece of evidence for the role of vitamin K in vascular health.

1D. The MK-4 Pharmacological Mechanism: The SXR Nuclear Receptor

At pharmacological doses (45 milligrams per day and above), MK-4 functions as a ligand for the steroid and xenobiotic receptor (SXR), a nuclear receptor that is distinct from the gamma-glutamyl carboxylase. SXR activation by MK-4 induces the expression of genes that promote bone formation, including alkaline phosphatase and osteopontin, and inhibits the expression of genes that drive osteoclast-mediated bone resorption. This is a transcriptional mechanism that is entirely independent of the cofactor function of vitamin K for the gamma-glutamyl carboxylase. It explains why the fracture reduction effect of MK-4 at 45 milligrams per day exceeds what would be predicted from the carboxylation of osteocalcin alone, and it distinguishes the pharmacological use of MK-4 from the nutritional use of MK-7. MK-7, at microgram-level nutritional doses, does not activate SXR; it functions solely through the carboxylation of the Gla-proteins.

---

Part 2. The Hepatic and Extrahepatic Gla-Proteome

The gamma-carboxylation of glutamic acid residues is an unusual and highly specialized post-translational modification. In the human proteome, fewer than 20 proteins are known to be gamma-carboxylated in a vitamin K-dependent manner. These can be divided into the hepatic coagulation factors and the extrahepatic Gla-proteins.

2A. The Hepatic Coagulation Factors

The liver synthesizes the vitamin K-dependent coagulation factors: prothrombin (Factor II), Factor VII, Factor IX, and Factor X, as well as the anticoagulant proteins C, S, and Z. The Gla domains of these proteins, which contain 9 to 12 Gla residues, are located at the amino terminus. Upon calcium binding, the Gla domain undergoes a dramatic conformational change that enables the protein to bind to phospholipid membranes, a requirement for the assembly of the tenase and prothrombinase complexes that amplify the coagulation cascade. The clinical test for vitamin K-dependent coagulation factor activity is the prothrombin time, expressed as the international normalized ratio (INR), which is sensitive to a reduction in the carboxylation state of the hepatic factors. The liver has a privileged access to vitamin K, preferentially taking up phylloquinone from the chylomicron remnant for the synthesis of the coagulation factors. This means that an INR that is in the normal range does not guarantee that the extrahepatic Gla-proteins are fully carboxylated. This concept, the dissociation between hepatic and extrahepatic vitamin K status, is the central diagnostic challenge in the clinical assessment of vitamin K sufficiency.

2B. Matrix Gla Protein: The Vascular Calcification Inhibitor

Matrix Gla Protein (MGP) is a small, 14-kilodalton protein secreted by vascular smooth muscle cells, chondrocytes, and fibroblasts. It is the most potent endogenous inhibitor of soft tissue calcification known. MGP requires two post-translational modifications for its biological activity: the vitamin K-dependent gamma-carboxylation of five glutamic acid residues, and a vitamin K-independent serine phosphorylation. The fully carboxylated and phosphorylated MGP binds to calcium ions and to nascent hydroxyapatite crystals in the extracellular matrix of the arterial media, physically preventing the growth and propagation of these crystals. It also inhibits the transdifferentiation of vascular smooth muscle cells from a contractile to an osteochondrogenic phenotype, a pathological process in which the smooth muscle cell begins to express bone-related genes, including alkaline phosphatase and osteocalcin, and deposits a mineralized matrix within the arterial wall.

In the absence of adequate vitamin K, MGP is undercarboxylated and is functionally inactive. The arterial smooth muscle cell, deprived of this inhibitory signal, undergoes osteochondrogenic differentiation, and the arterial media becomes a site of active, regulated mineralization that is histologically indistinguishable from bone. This is the mechanism of medial arterial calcification, a pathology that increases arterial stiffness, pulse wave velocity, and the risk of cardiovascular mortality. The measurement of the ratio of undercarboxylated MGP (dp-ucMGP) to carboxylated MGP in the plasma is a sensitive functional marker of vascular vitamin K status. An elevated dp-ucMGP indicates that the vascular smooth muscle cell does not have sufficient vitamin K to activate MGP and that the process of medial calcification is biochemically unchecked. This biomarker is now the gold standard for assessing extrahepatic vitamin K sufficiency in clinical research.

2C. Osteocalcin: The Bone Gla-Protein and Metabolic Hormone

Osteocalcin is a 49-amino acid protein secreted by the osteoblast during bone formation. It contains three Gla residues that mediate its binding to hydroxyapatite crystals in the bone matrix. The fully carboxylated osteocalcin is incorporated into the mineralizing bone, where it regulates the size and shape of the hydroxyapatite crystals and the rate of bone mineralization. In the absence of adequate vitamin K, the osteocalcin secreted by the osteoblast is undercarboxylated. This undercarboxylated osteocalcin (ucOC) is released into the circulation, where it functions not as a structural protein but as a hormone. Uncarboxylated osteocalcin binds to a specific G-protein-coupled receptor, GPRC6A, on the pancreatic beta cell, where it stimulates insulin secretion, and on the adipocyte, where it promotes adiponectin secretion and enhances insulin sensitivity. It also acts on the Leydig cells of the testis to stimulate testosterone synthesis and on the skeletal muscle to increase the uptake and utilization of glucose and fatty acids during exercise. This is the osteocalcin endocrine axis: the skeleton, through the vitamin K-dependent carboxylation state of osteocalcin, communicates with the pancreas, the adipose tissue, the muscle, and the gonad to regulate energy metabolism and fertility. The clinical measurement of the ratio of undercarboxylated to carboxylated osteocalcin is the functional biomarker of bone vitamin K status.

2D. Growth Arrest-Specific Protein 6 (Gas6)

Gas6 is a vitamin K-dependent protein that is structurally similar to the anticoagulant protein S and that functions as a ligand for the TAM family of receptor tyrosine kinases (Tyro3, Axl, Mer). The Gla domain of Gas6 mediates its binding to phosphatidylserine exposed on the surface of apoptotic cells. Through this binding, Gas6 acts as a bridging molecule that links the apoptotic cell to the TAM receptor on the surface of a macrophage, triggering the phagocytosis and clearance of the dying cell, a process known as efferocytosis. In the central nervous system, Gas6 is synthesized by neurons and glial cells and supports the survival of oligodendrocytes, the cells that synthesize the myelin sheath, and enhances the phagocytic clearance of myelin debris. Gas6 also plays a role in the regulation of the innate immune response, in the proliferation and survival of vascular smooth muscle cells, and in the maintenance of the blood-brain barrier.

2E. The Extended Gla-Protein Family: Periostin, PRGPs, and TMGs

The Gla-protein family extends beyond the well-characterized members. Periostin is a Gla-protein of the extracellular matrix involved in bone formation, wound healing, and the pathogenesis of cardiac fibrosis. The proline-rich Gla proteins (PRGP1, PRGP2) and the transmembrane Gla proteins (TMG3, TMG4) are of incompletely understood function but are expressed in the kidney, pancreas, and thyroid, suggesting roles in calcium handling and hormone secretion. These proteins collectively form the molecular infrastructure of calcium distribution, and their activity is contingent on adequate vitamin K status.

---

Part 3. The Clinical Biology of Vitamin K2: Vascular, Skeletal, Metabolic, and Reproductive Effects

The tissue-specific distribution of the menaquinones and the functional assessment of the extrahepatic Gla-proteins provide the mechanistic foundation for the clinical effects of vitamin K2.

3A. Vascular Calcification and Cardiovascular Mortality

The medial arterial calcification driven by undercarboxylated MGP is an active, cell-mediated process. The clinical correlate is an increase in arterial stiffness, measured as an elevated pulse wave velocity, which increases the afterload on the left ventricle and reduces coronary perfusion. The Rotterdam Study, a prospective cohort of over 4,800 older adults, found that the highest tertile of dietary menaquinone intake, predominantly MK-7, MK-8, and MK-9 from cheese and fermented foods, was associated with a 57 percent reduction in the risk of death from coronary heart disease and a 52 percent reduction in aortic calcification over a 10-year follow-up period. Dietary phylloquinone intake was not associated with these outcomes. A subsequent analysis found that high menaquinone intake was associated with a 20 percent reduction in all-cause mortality, driven primarily by the reduction in cardiovascular deaths.

Interventional trials have used arterial stiffness as a surrogate endpoint. A randomized, placebo-controlled trial in 244 postmenopausal women found that 180 micrograms per day of MK-7 for 3 years reduced arterial stiffness, as measured by carotid-femoral pulse wave velocity, and improved carotid artery distensibility and compliance compared to placebo. The effect was most pronounced in women with the highest baseline arterial stiffness. The measurement of dp-ucMGP in these trials confirmed that the effect of MK-7 on MGP carboxylation is dose-dependent and that a daily dose of 180 to 360 micrograms is sufficient to achieve a near-maximal reduction in dp-ucMGP in most individuals.

3B. Bone Mineral Density and Fracture Risk

The Japanese clinical trials of MK-4 at a pharmacological dose of 45 milligrams per day in postmenopausal women with osteoporosis have demonstrated a consistent reduction in the incidence of new vertebral fractures, with a pooled relative risk reduction of approximately 60 percent for vertebral fractures and 73 percent for hip fractures in a 2006 meta-analysis. This dose is pharmacological, not nutritional, and the mechanism involves both the carboxylation of osteocalcin and the SXR-mediated regulation of bone cell gene expression. The effect sizes reported in these trials are large and exceed those of many pharmacological osteoporosis therapies, though the trials were conducted in a single population and were not designed to current large, multi-center trial standards.

For nutritional-dose MK-7, a 2011 trial in 325 postmenopausal women found that 180 micrograms per day for 3 years reduced the age-related decline in bone mineral density at the lumbar spine and femoral neck and improved bone strength indices compared to placebo, but fracture endpoints were not assessed. The effect of nutritional-dose MK-7 on fracture risk remains unproven but is supported by the biomarker data showing a reduction in undercarboxylated osteocalcin.

3C. Insulin Sensitivity and Glucose Metabolism

Uncarboxylated osteocalcin, the form that is elevated in vitamin K deficiency, is the hormonally active metabolite that stimulates insulin secretion and enhances insulin sensitivity. This presents a metabolic paradox: vitamin K deficiency increases the uncarboxylated, hormonally active form of osteocalcin, which may be beneficial for glucose metabolism in the short term, but at the cost of impairing bone mineralization and activating vascular calcification. Clinical trials of vitamin K2 supplementation have shown mixed effects on insulin sensitivity. A 2018 meta-analysis of 8 randomized trials found that menaquinone supplementation, primarily MK-4 at doses of 30 to 45 milligrams per day, reduced fasting plasma glucose and hemoglobin A1c by a small but statistically significant margin, while phylloquinone had no effect. The clinical significance of this insulin-sensitizing effect is uncertain, and vitamin K2 is not a primary hypoglycemic agent.

3D. The Brain, the Nervous System, and Cognitive Function

The brain is a site of high menaquinone concentration, particularly MK-4, which is synthesized locally from phylloquinone by UBIAD1. The Gla protein Gas6 supports the survival of oligodendrocytes and the clearance of myelin debris by microglia, a pathway essential for the maintenance of white matter integrity. Vitamin K is also a component of the mitochondrial electron transport chain, where it functions as an electron carrier, a role independent of carboxylation. Epidemiological studies, including an analysis from the Quebec Longitudinal Study on Nutrition and Successful Aging, have found that higher dietary menaquinone intake, but not phylloquinone intake, is associated with better cognitive performance and a lower risk of cognitive decline. The hypothesis that vitamin K2 is a neuroprotective nutrient that slows the progression of age-related cognitive decline is mechanistically coherent but has not been tested in a randomized interventional trial with cognitive endpoints.

3E. Reproductive Biology: Testicular Function and Fertility

The testis expresses UBIAD1 and synthesizes MK-4 locally, and the concentration of MK-4 in the testis is among the highest of any tissue. The Leydig cells, which produce testosterone, and the Sertoli cells, which support spermatogenesis, are responsive to vitamin K2. A 2017 case series of men with infertility and low serum MK-4 levels reported an improvement in sperm count and motility after supplementation, though no randomized controlled trial has been conducted. The hypothesis that vitamin K2 supports testosterone synthesis and male fertility through a testicular Gla protein or through SXR-mediated regulation of steroidogenic enzyme expression is biologically coherent but clinically unvalidated.

3F. Dental and Craniofacial Development

The dentin of teeth and the alveolar bone of the jaw express osteocalcin and MGP, and vitamin K-dependent carboxylation is essential for proper mineralization. The developing craniofacial skeleton is sensitive to vitamin K status; maternal vitamin K deficiency induced by warfarin during the first trimester produces warfarin embryopathy, characterized by nasal hypoplasia and stippled epiphyses. The role of vitamin K2 in the prevention of dental caries and periodontal disease is supported by mechanistic rationale but not by clinical trials.

---

Part 4. The Clinical Taxonomy of Vitamin K Insufficiency

Vitamin K insufficiency is a condition that is defined not by the prothrombin time but by the undercarboxylation of the extrahepatic Gla-proteins, a state that can exist in the presence of a perfectly normal INR.

4A. The Hepatic-Extrahepatic Dissociation

The liver has a privileged access to dietary vitamin K, and it can maintain the carboxylation of the coagulation factors even when the supply of vitamin K is insufficient for the extrahepatic tissues. The clinical consequence is that a patient can have a normal INR, indicating adequate hepatic vitamin K status, while simultaneously having an elevated dp-ucMGP and an elevated undercarboxylated osteocalcin, indicating inadequate extrahepatic vitamin K status. This is the concept of subclinical vitamin K deficiency, a state that is not recognized by standard coagulation assays. The prevalence of this state in the general population is high; studies using the measurement of undercarboxylated osteocalcin have found that a substantial fraction of apparently healthy adults, estimated at 30 to 50 percent in Western populations, have evidence of suboptimal vitamin K status for bone metabolism.

4B. High-Risk Populations

The populations at highest risk for extrahepatic vitamin K insufficiency are those with a low dietary intake of menaquinones, which includes most individuals who do not regularly consume natto, organ meats, or fermented foods, and those on long-term warfarin therapy, in whom the pharmacological inhibition of VKORC1 produces a systemic, functional vitamin K deficiency that affects all tissues. Patients with chronic kidney disease, particularly those on dialysis, have accelerated medial arterial calcification driven in part by a deficiency of MGP carboxylation, and they are a population of intense interest for vitamin K2 intervention. Patients with fat malabsorption syndromes, the obese, and the elderly are also at elevated risk.

---

Part 5. The Evidence Mapped by Quality and Clinical Application

The clinical evidence for vitamin K2 is most mature for bone and arterial health, where both epidemiological and interventional data support a protective effect.

5.1. Fracture Risk Reduction: The MK-4 Pharmacological Model

The Japanese trials of MK-4 at 45 milligrams per day for postmenopausal osteoporosis provide the strongest evidence for a fracture reduction benefit. The 2006 meta-analysis by Cockayne and colleagues, reporting a 60 percent reduction in vertebral and a 73 percent reduction in hip fractures, is the basis for the approval of MK-4 as an osteoporosis therapy in Japan. The limitation of this evidence is that the trials were conducted in a single population and were not designed to current large, multi-center trial standards.

5.2. Arterial Calcification and Cardiovascular Mortality: The MK-7 Nutritional Model

The Rotterdam Study and the subsequent interventional trials of MK-7 at 180 to 360 micrograms per day establish a nutritional basis for the cardiovascular protection of vitamin K2. The 57 percent reduction in coronary heart disease mortality in the highest tertile of dietary menaquinone intake, and the reduction in arterial stiffness with MK-7 over 3 years, are the most compelling human data for the recommendation of dietary or supplemental menaquinone for long-term cardiovascular health.

5.3. The Coagulation Safety Profile

Trials of MK-7 at doses up to 360 micrograms per day for up to 3 years have shown no increase in thrombotic events, no changes in prothrombin time or activated partial thromboplastin time, and no increase in markers of thrombin generation. The gamma-glutamyl carboxylase in the liver is saturable, and once the prothrombin time is normalized, additional vitamin K does not generate excess clotting factor activity. For patients on direct oral anticoagulants, which do not target VKORC1, vitamin K2 does not interfere with their mechanism of action.

---

Part 6. A Clinical Dosing Compendium

The therapeutic use of vitamin K2 is defined by the distinction between the nutritional maintenance of the extrahepatic Gla-proteins with MK-7 and the pharmacological activation of the SXR nuclear receptor with MK-4.

6.1. Evidence-Based and Guideline-Supported Protocols

Prevention of Vitamin K Deficiency Bleeding in the Newborn. The standard of care is a single intramuscular dose of 1 milligram of phylloquinone (K1) administered immediately after birth. This is not a vitamin K2 intervention.

Reversal of Warfarin Anticoagulation. For life-threatening bleeding, the protocol is 10 milligrams of intravenous phylloquinone, administered slowly, in combination with prothrombin complex concentrate.

6.2. Nutritional and Pharmacological Protocols for Extrahepatic Indications

Vascular Calcification and Arterial Stiffness Reduction. The evidence-based dose is MK-7 at 180 to 360 micrograms per day, taken orally with a fat-containing meal. The monitoring of dp-ucMGP, with a target of a reduction to the lower end of the normal reference range, provides biochemical confirmation of the adequacy of the intervention. The duration of therapy for the prevention of age-related arterial calcification is indefinite.

Pharmacological Osteoporosis Therapy with MK-4. The evidence-based dose is 45 milligrams per day of MK-4, divided into three doses of 15 milligrams each, taken with meals. This is a pharmacological agent that should be prescribed in the context of a comprehensive osteoporosis management plan that includes adequate calcium and vitamin D.

Nutritional Bone Health Support with MK-7. The nutritional approach, applicable to the general population of postmenopausal women, is MK-7 at a dose of 180 to 360 micrograms per day, in combination with vitamin D and adequate calcium.

Warfarin Anticoagulation Management. The principle is the consistency of intake. A stable daily intake of vitamin K2 can be accommodated by adjusting the warfarin dose. A patient who initiates vitamin K2 supplementation at 100 to 200 micrograms per day while on warfarin should have the INR checked within 1 to 2 weeks, and the warfarin dose adjusted as needed.

6.3. Universal Principles Governing Vitamin K2 Supplementation

MK-4 and MK-7 Are Not Interchangeable. MK-4 has a short half-life, requires high pharmacological doses for SXR-mediated effects on bone, and is the preferred form for the treatment of established osteoporosis. MK-7 has a long half-life, achieves complete carboxylation of extrahepatic Gla-proteins at microgram-level nutritional doses, and is the preferred form for the long-term prevention of arterial calcification and the maintenance of bone health in the general population.

The Biomarker for Extrahepatic Vitamin K Status Is dp-ucMGP. The measurement of dephosphorylated, uncarboxylated matrix Gla protein in the plasma is the most sensitive and specific functional marker of vitamin K status in the arterial wall and other extrahepatic tissues. Plasma undercarboxylated osteocalcin provides a complementary measure of bone vitamin K status.

The Vitamin D-Vitamin K2-Calcium Triad. Vitamin D stimulates the synthesis of MGP and osteocalcin. Vitamin K2 carboxylates them. Calcium is the mineral they chaperone. The prescription of vitamin D and calcium for osteoporosis without ensuring adequate vitamin K status is a physiologically incomplete intervention. The clinical approach that is consistent with the biology is to ensure the adequacy of all three nutrients.

---

Part 7. The Unresolved Frontier

Three questions define the current limit of vitamin K2 science.

Can Long-Term MK-7 Supplementation Reduce the Incidence of Cardiovascular Events in a Primary Prevention Population? The definitive trial, a randomized, placebo-controlled, event-driven study of MK-7 at 360 micrograms per day in a population at intermediate cardiovascular risk, has not been conducted. This is the evidence required to move vitamin K2 from a nutritional intervention for vascular health to a standard of care for the prevention of cardiovascular disease.

What Is the Function of Vitamin K2 in the Mitochondrion, and Can It Be Therapeutically Exploited? The identification of menaquinones as components of the mitochondrial electron transport chain opens a new field of vitamin K biology that is entirely independent of carboxylation. If vitamin K2 is a rate-limiting cofactor for mitochondrial ATP production in neurons, skeletal muscle, and the cardiac myocyte, a deficiency could contribute to the mitochondrial dysfunction that underlies aging, neurodegeneration, and heart failure.

Is Vitamin K2 a Geroprotective Nutrient? The inhibition of arterial calcification, the support of bone mineralization, the maintenance of myelin integrity through Gas6, and the modulation of insulin sensitivity through osteocalcin position vitamin K2 at the intersection of several aging-relevant pathways. The hypothesis that a chronic, subclinical vitamin K2 insufficiency is a contributor to the multi-morbidity of aging (osteoporosis, arterial stiffness, cognitive decline, and insulin resistance) is mechanistically coherent. The test of this hypothesis would be a randomized trial of MK-7, initiated in midlife and continued for 10 to 15 years, with a composite primary endpoint of incident fracture, major adverse cardiovascular events, and cognitive decline. Such a trial would be large, prolonged, and expensive, but it is the only design that can determine whether vitamin K2 is a geroprotective nutrient.

---

Part 8. Synthesis for an Evidence-Based Approach

Vitamin K2 is the calcium-distribution vitamin. Its primary function is to activate a family of Gla proteins that ensure hydroxyapatite is deposited in bone and dentin and is inhibited in the arterial wall, the kidney, and the brain. The clinical evidence supports its role in the prevention of arterial calcification and cardiovascular mortality, with a 180 to 360 microgram per day dose of MK-7 reducing arterial stiffness and coronary heart disease mortality. The evidence supports the pharmacological use of MK-4 at 45 milligrams per day for the reduction of fractures in postmenopausal osteoporosis, an effect that likely involves both the carboxylation of osteocalcin and the SXR-mediated regulation of bone cell gene expression.

The distinction between phylloquinone and the menaquinones is clinically significant. Phylloquinone is the hepatic coagulation vitamin. Menaquinones, particularly MK-7, are the extrahepatic Gla-protein vitamins. The dietary intake of menaquinones in Western populations is low, and a substantial fraction of otherwise healthy adults have biochemical evidence of subclinical vitamin K2 insufficiency, as indicated by elevated dp-ucMGP. The long-term consequences of this insufficiency are likely to include accelerated arterial calcification, increased fracture risk, and possibly cognitive decline.

The clinical integration of vitamin K2 into practice requires the measurement of dp-ucMGP to identify the insufficient patient, the selection of MK-7 for nutritional prevention and MK-4 for pharmacological osteoporosis treatment, the co-administration of vitamin D and adequate calcium, and the indefinite continuation of therapy to maintain the carboxylation of the Gla proteins. The safety profile of nutritional doses of MK-7 is excellent, with no evidence of thrombotic risk.

The frontier of vitamin K2 research is the test of the geroprotective hypothesis: that a lifetime of adequate menaquinone intake slows the age-related calcification of the vascular tree, the loss of bone mass, and the decline in cognitive function that together define the morbidity of aging. The answer to that question will require trials of a scale and duration that have not yet been undertaken, but the biology of the Gla proteins provides a firm mechanistic foundation for the enterprise. For the present, the clinician's duty is to recognize the hepatic-extrahepatic dissociation that defines subclinical vitamin K insufficiency, to restore the menaquinone supply to the tissues that depend on it, and to wield this ancient and specific cofactor with the understanding that the distribution of calcium within the body is a process that is as actively regulated as the calcium concentration in the blood, and that vitamin K2 is the essential cofactor for that regulation.